Debasish Roychowdhury of Sanofi-Aventis says the cancer unit will focus on fewer drugs that have greater potential for success.
Sanofi seeks efficiencies with new model
Debasish Roychowdhury of Sanofi-Aventis says the cancer unit will focus on fewer drugs that have greater potential for success.
The placement of a joint headquarters of Sanofi-Aventis SA’s new cancer research unit in Cambridge, announced last month, marks a turning point for the world’s third-largest pharmaceutical company. (Full article: 903 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
